Compliance with current guidelines might result in more patients dying of multi-drug-resistant pneumonia in intensive care units

January 19, 2011

Adhering to the current guideline recommendations for the treatment of intensive-care patients at risk of infection with multi-drug resistant (MDR) pneumonia might be associated with an increased risk of death. The findings, published in an Article Online First in The Lancet Infectious Diseases, highlight the need for The American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) guidelines to be reassessed.

The current ATS-IDSA guidelines for the management of hospital-acquired, ventilator-associated, and health-care associated pneumonias recommend prompt empirical antibiotic treatment (before the culture results are known) of patients at risk of multi-resistant infection. According to the guidelines, these patients should be given a triple regimen of antibiotics--a combination of two drugs against Gram-negative pathogens and one against meticillin-resistant Staphlococcus aureus (MRSA)--so that at least one drug is active against any likely infectious agent. However, since the publication of the guidelines in 2005, several studies have failed to a show a benefit of dual Gram-negative therapy over monotherapy.

The Improving Medicine through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study was a performance improvement project designed to validate the current ATS-IDSA guidelines and assess the observance of the treatment recommendations and outcomes of patients at risk for MDR pneumonia.

303 patients at risk of MDR pneumonia were enrolled from four academic centres across the USA. 129 patients were given guideline-compliant antibiotic treatment, and 174 patients received non-compliant treatment.* In these patients at risk for MDR infections, the Kaplan-Meier estimate of survival to 28 days was 65% in the compliant group and 79% in the non-compliant group. The difference in survival remained after adjustment for severity of illness.

The authors say: "Our results further question the need for combination Gram-negative empirical treatment for patients with pneumonia, even those who are severely ill and at risk of multi-drug resistant pathogens."

They conclude: "[We] recommend that the planned, revised ATS-IDSA guidelines be reassessed before widespread implementation. Since the most common reason for non-compliance was failure to use a secondary anti-Gram-negative drug, we suggest a comparison of regimens employing MRSA treatment and single versus dual Gram-negative coverage."

In a Comment, Santiago Ewig from the Center for Thoracic Diseases of the Ruhrgebiet, Bochum, Germany, questions the validity of the findings, but points out that the recommended triple approach is not supported by the available evidence and is not necessarily correct: "All patients with septic shock, and probably severe sepsis, should receive dual coverage or triple coverage if MRSA is indicated. Whether all haemodynamically stable patients with nosocomial pneumonia need such a wide coverage is questionable; at least, de-escalation [ie, monotherapy] treatment is mandatory, since it reduces selection pressure, organ toxic effects, and saves money. After all, de-escalation is what matters. The definition of non-adherence to American Thoracic Society guidelines should not read 'less than triple therapy' but rather 'less than long-term prognosis and risk-adjusted broad coverage and de-escalation according to culture and susceptibility results'."
Professor Daniel Kett, the Miller School of Medicine at the University of Miami, Miami, Florida, USA. T) +1 (305) 585 6664 E)

Dr Santiago Ewig, Center for Thoracic Diseases of the Ruhrgebiet, Bochum, Germany. E)

For full Article and Comment see:

Notes to Editors: *Non-compliance included failure to use a second anti-Gram-negative drug (154 patients) and failure to use either a primary anti-Gram-negative drug (24 patients) or an anti-MRSA drug (24 patients).



Related Pneumonia Articles from Brightsurf:

Vaccine proves effective against the most severe type of pneumonia
A pneumococcal vaccine was effective at protecting children in Laos against the most severe type of pneumonia, a new study has found.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

Elderly patients with pneumonia twice as likely to die as those with broken hips, yet underestimate the danger of pneumonia
Elderly patients who are hospitalised with pneumonia are twice as likely to die as those hospitalised with hip fractures -- yet many elderly people fail to accurately assess their risk of pneumonia, concludes research due to be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Pneumonia recovery reprograms immune cells of the lung
Researchers have determined that after lungs recover from infection, alveolar macrophages (immune cells that live in the lungs and help protect the lungs against infection) are different in multiple ways and those differences persist indefinitely.

Skin and mucous membrane lesions as complication of pneumonia
Painful inflammatory lesions of the skin and mucous membranes may occur in children who develop bacterial pneumonia.

Vaccine reduces likelihood of severe pneumonia
A new study has found severe pneumonia decreases by 35 per cent in children who receive a vaccine against a pneumonia-causing bacteria.

Bacteria in pneumonia attack using bleaching agent
Research shows that bacteria use hydrogen peroxide to weaken the immune system and cause pneumonia.

Many kids with pneumonia get unnecessary antibiotics, chest X-rays
Preschool children with community-acquired pneumonia often receive unnecessary tests and treatment at outpatient clinics and emergency departments, according to a nationally representative study led by Todd Florin, M.D., MSCE, from Ann & Robert H.

Certain psychiatric drugs linked with elevated pneumonia risk
A review of published studies indicates that use of benzodiazepines and benzodiazepine related drugs (BZRDs), which are prescribed to treat various psychiatric diseases, may increase the risk of pneumonia.

Bacterial pneumonia far more dangerous to the heart than viral pneumonia, study finds
Heart complications in patients diagnosed with bacterial pneumonia are more serious than in patients diagnosed with viral pneumonia, according to new research.

Read More: Pneumonia News and Pneumonia Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to